News headlines about Ascendis Pharma A/S (NASDAQ:ASND) have been trending somewhat positive recently, according to AlphaOne Sentiment. AlphaOne, a service of Accern, scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ascendis Pharma A/S earned a news sentiment score of 0.09 on AlphaOne’s scale. AlphaOne also gave headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the next few days.

Insider Buying and Selling by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Shares of Ascendis Pharma A/S (NASDAQ:ASND) traded up 3.45% on Friday, hitting $24.00. 54,135 shares of the company’s stock were exchanged. Ascendis Pharma A/S has a 12-month low of $12.34 and a 12-month high of $31.86. The stock’s market cap is $780.05 million. The company’s 50-day moving average price is $25.93 and its 200 day moving average price is $24.96.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, May 23rd. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.19. Ascendis Pharma A/S had a negative return on equity of 58.53% and a negative net margin of 1,944.88%. The business had revenue of $0.40 million for the quarter, compared to analyst estimates of $1.10 million. On average, equities analysts predict that Ascendis Pharma A/S will post ($3.42) earnings per share for the current fiscal year.

Several research analysts recently commented on ASND shares. Zacks Investment Research lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Thursday, February 16th. Wedbush restated an “outperform” rating and set a $31.00 target price on shares of Ascendis Pharma A/S in a research report on Thursday, February 23rd. Leerink Swann lowered Ascendis Pharma A/S from an “outperform” rating to a “market perform” rating and boosted their target price for the company from $24.00 to $30.00 in a research report on Thursday, March 9th. J P Morgan Chase & Co assumed coverage on shares of Ascendis Pharma A/S in a research note on Thursday, May 11th. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, ValuEngine raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, May 27th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Ascendis Pharma A/S has a consensus rating of “Hold” and a consensus price target of $29.60.

COPYRIGHT VIOLATION NOTICE: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.